Gilead to withdraw Trodelvy cancer drug from Greece

The pharmaceutical company Gilead has decided to withdraw the oncology drug Trodelvy (sacituzumab govitecan) from the Greek market by the end of the year. The medication is used to treat metastatic, triple-negative, and hormone-sensitive breast cancer, an aggressive form of the disease.

Industry sources and medical professionals indicate the withdrawal is driven by the high clawback mechanism in Greece, where pharmaceutical companies must make mandatory financial returns to the state. In some cases, these burdens can reach 80%, making it commercially unviable to distribute certain innovative treatments. Negotiations between Gilead and the Drug Price Negotiation Committee reportedly failed to reach an agreement on pricing.

The Hellenic Society of Medical Oncologists (EOPΕ) has sent a letter to Health Minister Adonis Georgiadis, calling for immediate institutional dialogue to create a more predictable and sustainable framework for oncological innovation. The society warns that without structural reforms to ensure both fiscal stability and the availability of effective therapies, patients will continue to lose access to life-saving medicines. This marks the fourth oncology drug to be withdrawn from the Greek market in recent months.